Stockscreener 앱 받기
592.62
0.16%
-0.801
전일 마감가:
$591.82
열려 있는:
$587.39
하루 거래량:
204.30K
Relative Volume:
0.83
시가총액:
$35.30B
수익:
$1.86B
순이익/손실:
$-40.29M
주가수익비율:
-142.46
EPS:
-4.16
순현금흐름:
$-1.28B
1주 성능:
-0.70%
1개월 성능:
+5.43%
6개월 성능:
+65.66%
1년 성능:
+20.92%
1일 변동 폭
$582.07
$594.67
1주일 범위
$558.15
$594.67
52주 변동 폭
$327.73
$611.22
알제넥스 NV ADR Stock (ARGX) Company Profile
ARGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ARGX | 592.38 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| VRTX | 450.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ALNY | 246.25 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.35 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com
Barclays bullish on argenx stock after positive trial results - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Inkl
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
Argenx shares target lifted, overweight on Vyvgart sales beat - Investing.com
argenx stock downgraded after 65% rally, Baird cites limited short-term upside - Investing.com India
William Blair bullish on argenx stock as Vyvgart flexes in CIDP and eyes new horizons - Investing.com India
Raymond James maintains outperform on argenx, cites strong sales - Investing.com India
argenx stock climbs as Truist highlights industry-leading I&I pipeline growth - Investing.com India
Stifel sees upside in argenx stock with robust pipeline and solid 3Q results - Investing.com
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP - Investing.com Nigeria
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $589.6 amid robust growth - Investing.com
argenx ADR earnings beat by $1.24, revenue topped estimates - Investing.com
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - The Bakersfield Californian
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - GlobeNewswire Inc.
argenx SE's SWOT analysis: biotech firm's stock poised for growth amid challenges - Investing.com
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $555.55 amid robust growth - Investing.com
Argenx stock soars to all-time high of $555.55 amid robust growth By Investing.com - Investing.com South Africa
Jefferies’ updated ‘Franchise picks’: CPAY, KVUE, SAIA, PFGC (S&P Complete Indices:SP500) - Seeking Alpha
argenx shares receive Strong Buy rating on CIDP approval - Investing.com India
Piper Sandler maintains Overweight rating on argenx shares - Investing.com
Deutsche Bank downgrades argenx shares, keeping price target steady amid incremental caution - Investing.com India
Halozyme expands argenx collaboration with $30M deal - Investing.com
Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs - Investor's Business Daily
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.58%
자본화:
|
볼륨(24시간):